Numis Securities Ltd reaffirmed their add rating on shares of Hvivo PLC (LON:HVO) in a research report report published on Thursday. The firm currently has a GBX 210 ($2.74) price objective on the stock.
Hvivo PLC (LON:HVO) opened at 181.00 on Thursday. Hvivo PLC has a one year low of GBX 167.00 and a one year high of GBX 285.00. The company’s 50-day moving average is GBX 180.10 and its 200 day moving average is GBX 186.43. The firm’s market cap is GBX 141.30 million.
In other Hvivo PLC news, insider Ellertson,Jaime bought 7,801 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were acquired at an average cost of GBX 187 ($2.44) per share, for a total transaction of £14,587.87 ($19,041.73).
About Hvivo PLC
hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold.
Receive News & Ratings for Hvivo PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo PLC and related companies with MarketBeat.com's FREE daily email newsletter.